Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Working Capital Changes (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Other Working Capital Changes over the past 3 years, most recently at -$285000.0 for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$285000.0 for Q4 2025, down 143.38% from a year ago — trailing twelve months through Dec 2025 was -$303000.0 (down 2230.77% YoY), and the annual figure for FY2025 was -$303000.0, down 2230.77%.
  • Other Working Capital Changes for Q4 2025 was -$285000.0 at Tonix Pharmaceuticals Holding, up from -$501000.0 in the prior quarter.
  • Over the last five years, Other Working Capital Changes for TNXP hit a ceiling of $657000.0 in Q4 2024 and a floor of -$1.6 million in Q4 2023.
  • Median Other Working Capital Changes over the past 3 years was -$69500.0 (2023), compared with a mean of -$157416.7.
  • Biggest five-year swings in Other Working Capital Changes: crashed 285.17% in 2024 and later surged 30750.0% in 2025.
  • Tonix Pharmaceuticals Holding's Other Working Capital Changes stood at -$1.6 million in 2023, then soared by 141.14% to $657000.0 in 2024, then crashed by 143.38% to -$285000.0 in 2025.
  • The last three reported values for Other Working Capital Changes were -$285000.0 (Q4 2025), -$501000.0 (Q3 2025), and -$134000.0 (Q2 2025) per Business Quant data.